Topic summary

Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version

Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide SURPASS programme Closed

This is a generated summary. It shows the 9 most-liked posts from a topic of 91, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

o.lindgrenTL2Regular28 Nov 2025 · edited#3

s.chowdhury, post #1: On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2 diabetes, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no… Go to post

This follows the opening post rather than contradicting it.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

The uncertainty is in the assumption, not in the calculation.

32 likes in reply to #1 8mo

b.vanheckeTL230 Nov 2025 · edited#10

m.strand_rph, post #9: Thank you for the correction. I would rather find out here than later. Go to post

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Two sources, same conclusion, and I could not rule out that one copied the other.

30 likes in reply to #9 8mo

k.farrugiaTL3Regular1 Dec 2025#16

Quietly grateful for the plain phrasing. Not every thread gets that.

30 likes 8mo

dr_seongTL3Physician3 Dec 2025#23

Building on post #20 rather than restating it.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

That has held every time I have looked, which is not the same as always.

27 likes 8mo

m.lehtinenTL24 Dec 2025#30

ro.frisk, post #24: Post #22 put the caveat in the right place and I want to underline it. Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the… Go to post

I read post #26 twice before replying, because I had assumed the opposite.

The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement for smaller steps.

That has been true for the cases I have seen and I have not seen many.

26 likes in reply to #24 8mo

d.achebeTL24 Dec 2025#33

Careful with the language on Tirzepatide in type 2 diabetes. "Not detected" and "not present" are different findings and the first is a statement about the method.

26 likes 8mo

c.chowdhuryTL26 Dec 2025#43

Useful. I had the fact and not the reason, which turns out to be the important half.

33 likes 8mo

y.adeyemiTL27 Dec 2025#47

Post #46 is right about the mechanism and I think understates the practical bit.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

Written from notes rather than memory, which is why the numbers are specific.

25 likes 8mo

cannula_driftTL3Regular11 Dec 2025#77

On Tirzepatide in type 2 diabetes I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

33 likes 8mo

Read the full topic (91 posts)

This topic was referenced in

Reading SURMOUNT-1 without the press release — one year onCompounds › Tirzepatide · 50 replies

This topic was closed 30 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…	+15	19	930	18mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…	+101	111	1.5k	18mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
Tirzepatide storage and stability: what is published versus what is assumed Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…	+17	21	17k	12d
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo

Related topics — sharing the tags SURMOUNT programme, randomised trial, effect size

Topic	Participants	Replies	Views	Activity
Comparing my trajectory with the trial curves, carefully — a second dataset Outcomes › Progress reports effect size data table long read Comparing my trajectory with the trial curves, carefully — a second dataset — setting out what I have, and where I think it stops being reliable. Maintenance rather than loss, which is the part of this that…	+77	81	16k	11h
Revisiting: Holding a dose indefinitely: is there a documented downside? Practice › Dosing & titration titration tirzepatide worked example missed dose Solved The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this…	+26	30	4.5k	18mo
Journal club: PIONEER 6 as a safety trial Evidence › Journal club effect size journal club number needed to treat risk of bias Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Reading PIONEER 6 ( N Engl J Med , 2019) for the population rather than the…	+14	18	262	5mo
[2026 update] What steady state means for the decision to escalate Practice › Dosing & titration tirzepatide worked example semaglutide missed dose The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…	+127	137	32k	8mo
Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide STEP programme SELECT trial randomised trial effect size Solved Closed Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…		2	63k	5mo